Hims & Hers Faces a Pivotal Challenge to Its Profit Model

Despite strong earnings, Hims & Hers stock drops as FDA rules end lucrative compounded GLP-1 drugs, pressuring margins. Insider sales and a legal probe add to investor concerns.

Despite posting impressive quarterly earnings, shares of Hims & Hers are under significant pressure. Investor skepticism is mounting as a mandated strategic shift in its lucrative weight-loss medication business forces a fundamental reassessment of the company's future profitability, sending its stock price downward.

Insider Activity and Legal Scrutiny Add to Concerns

Adding to the headwinds, company insiders have sold shares worth approximately $3.46 million over the past three months. Concurrently, the Schall Law Firm has announced an investigation into potential securities law violations. These developments contribute to a climate of uncertainty around the stock.

Regulatory Shift Squeezes Profits

The immediate cause of the recent decline, which saw shares fall over six percent, is a regulatory change. The U.S. Food and Drug Administration (FDA) has signaled an end to supply shortages for GLP-1 medications. This move eliminates a special allowance for highly profitable, custom-compounded versions of these drugs, forcing Hims & Hers to alter its offering.

The platform now distributes official brand-name products like Wegovy and Ozempic for $149 per month. While this step resolves an ongoing patent dispute with Novo Nordisk and secures the company's legal standing, it comes at a cost. The expensive original medications are putting noticeable pressure on the firm's profit margins, transforming a former margin driver into a more standard product line.

Strong Quarterly Performance Overshadowed

This cloudy outlook overshadows what was otherwise a robust financial report. For the fourth quarter of 2025, the company reported earnings of $0.08 per share, soundly beating consensus estimates of $0.02. Revenue also saw substantial year-over-year growth of 28.4%, reaching nearly $618 million.

Nevertheless, analysts are reacting cautiously due to the margin compression. Investment bank TD Cowen yesterday lowered its price target from $25 to $23, maintaining a "hold" rating on the shares. The current average market price target stands at $31.71.

A Defining Year Ahead

With a loss of roughly 40% since the start of the year, the stock now trades at $19.46, a far cry from its high of over $66 last summer. The company's market capitalization is approximately $4.75 billion. The enforced transition to lower-margin original pharmaceuticals represents a stern test for the existing growth model and is fundamentally redefining the financial framework for the current fiscal year.